DIRECT TO PHASE II: Minimally Invasive Remote Blood Collection Device for Free-Ranging Cetaceans

SBIR · Phase: BOTH · Topic DON26BZ06-DV088 · Solicitation 26.BZ

Navy bottlenose dolphins are valuable Fleet assets whose health and well-being are essential to sustaining mine countermeasures, port security, and object recovery missions. Medical issues compromise performance and have direct implications for Navy mission readiness, longevity, and reliability. Additionally, for the U.S. Navy to meet environmental compliance requirements under the Marine Mammal Protection Act and Endangered Species Act, it is essential to understand the effects of sound and military activity on marine mammals, including physiological, behavioral, ecological, and population-level effects. While technologies and techniques for assessing marine mammal health are growing rapidly, many barriers remain for these Fleet assets as well as other free-swimming large cetacean species that can be used as biological sensors of the undersea environment. A transformative diagnostic tool will provide unparalleled access to physiological data and biomarkers of health, stress, and disease from free-swimming cetaceans with applications in clinical care, operational biosurveillance, and conservation. Blood sampling of captive trained dolphins and/or stranded marine mammals enables researchers to evaluate individual and population health, age, genetics, exposure to pathogens and toxicants, and physiological responses to anthropogenic and natural stressors. By enabling minimally invasive blood sampling in free-ranging cetaceans, these animals can be used as biological sensors for persistent surveillance of the undersea environment, providing early warning of pathogens and other ecosystem stressors in operational waters. However, current blood collection methods in marine mammals are designed for use on stranded or captured individuals and are therefore limited in their capability of rapidly assessing health for larger free-swimming species. The lack of such a tool for health assessments is particularly urgent for Fleet animals and free-ranging animals in the region of deployment, where timely and accurate health assessments are essential for informing recovery efforts and mitigating population decline. As such, there is a critical need for a minimally invasive blood collection tool for remote application to the skin of free-ranging cetaceans to address significant gaps and improve our understanding of marine mammal health across spatiotemporal scales, providing unprecedented data on physiological responses, health metrics, and population dynamics. This SBIR Direct to Phase II topic seeks to develop a prototype minimally invasive blood collection device for remote application on free-ranging cetaceans by further developing an existing capillary blood collection device initially designed for humans. This prototype device should be able to be remotely deployed using current techniques used for the deployment of suction-cup electronic tags on free-ranging marine mammals (i.e., pole-based or drone dropped) under diverse environmental conditions. This prototype will include a blood collection device, waterproof housing, delivery device using suction cup tag carrier, and suction cup-based tag attachment. This prototype waterproof device should be capable of remotely deployable blood collection across cetacean species of varying epidermal thickness. The target size and weight of the blood collection device (not including the suction cup housing) should be approximately 3.40x2.25x1.30 in in size and weigh between 0.85 and 0.95 oz. This prototype device should sit flush and seal against the skin and use suction to draw 200-800 uL of capillary blood with minimal clotting into an internal reservoir (independent of orientation) and mix the sample with anticoagulants or other stabilization chemicals. At minimum the Phase II prototype should be able to collect blood samples from species with epidermis of < 2.5 mm thickness with a plan to successfully collect blood samples from species with epidermal thickness of > 10 mm. During this collection p…

SBIR/STTR 은 미국 중소기업만 지원할 수 있습니다(Small Business Act 법정 요건). • 계열사를 포함해 상시 종업원 500명 이하 • 미국 시민 또는 영주권자 1인 이상이 50%를 초과해 직접 소유·지배 • 미국 내 사업장을 두고 주로 미국 내에서 사업을 영위할 것 • 수행책임자(PI)의 주된 근무처가 신청 기업일 것 출처: https://www.sbir.gov/faq/eligibility-requirements

Primary country

🇺🇸 United States

Also eligible

None

Foreign companies

No

Local entity

Required

Location condition

미국 내 사업장을 두고 미국 시민·영주권자가 50%를 초과해 소유한 중소기업만 신청할 수 있습니다(법정 요건).

Document requirements were not captured (needs verification). Check the official announcement.

Application process not captured.

Evaluation process not captured.

Process steps were not captured.

No risk assessment yet. Re-analyse from Admin.

No IP assessment yet.

Official URL

https://www.dodsbirsttr.mil/topics-app/

Application URL

https://www.dodsbirsttr.mil/topics-app/

Last fetched

2026.10.07

Human review

Not reviewed — check the official announcement

First seen

2026.10.07

Data status

Auto-collected, not reviewed

AI enrichment

Needs verification